Filter
Period
Filter by
recent search
Showing: 1 – 05 of 152 Regulated Information
–
29 June 2023
29 June 2023
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 29 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of investigational palovarotene as an effective treatment, with a…
–
27 June 2023
27 June 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2023
Aggregated presentation by day and by market
–
20 June 2023
20 June 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
Aggregated presentation by day and by market
–
19 June 2023
19 June 2023
–
14 June 2023
14 June 2023
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
PARIS, FRANCE, 14 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen)…